PMID- 29434844
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 15
IP  - 2
DP  - 2018 Feb
TI  - Oxaliplatin and infliximab synergize to induce regression of colon cancer.
PG  - 1517-1522
LID - 10.3892/ol.2017.7468 [doi]
AB  - There is currently a lack of therapeutic options for patients with advanced colon 
      cancer. Although certain chemotherapies are able to suppress the progression 
      slightly, the response rate is low, and side effects of treatment and tumor 
      recurrence continue to present problems for clinicians. Tumor necrosis factor-alpha 
      (TNF-alpha) has been identified to possess tumor-promoting properties. In the present 
      study, the effect of anti-TNF-alpha treatment (infliximab) in combination with 
      chemotherapy on colon cancer was investigated. Tumor tissue samples were 
      collected from patients with colon cancer who received oxaliplatin (OXA) 
      treatment. Their TNF-alpha expression levels were examined with regard to their 
      sensitivity to OXA. OXA-resistant colon cancer cell lines were established to 
      explore the effects of anti-TNF-alpha treatment and OXA treatment. Furthermore, an 
      OXA-resistant colon cancer xenograft mouse model was created and the effects of 
      the combination treatment of anti-TNF-alpha and OXA on the mice were assessed. The 
      results of the present study indicated that TNF-alpha was increased in the tumor 
      tissue of patients with colon cancer who were resistant to OXA and also in 
      OXA-resistant colon cancer cell lines. Anti-TNF-alpha treatment using infliximab 
      inhibited the survival of OXA-resistant colon cancer cell lines by inducing 
      antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity 
      effects. The combination of infliximab and OXA treatment achieved increased 
      efficacy on the OXA-resistant colon cancer xenograft mouse model compared with 
      treatment with OXA alone. On the basis of the results of the present study, it 
      was concluded that infliximab may sensitize colon cancer cells to OXA treatment.
FAU - Huang, Di
AU  - Huang D
AD  - Department of Gastrointestinal Surgical Oncology, The First Affiliated Hospital 
      of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China.
FAU - Xue, Jun
AU  - Xue J
AD  - Department of Vascular and Gland Surgery, The First Affiliated Hospital of Hebei 
      North University, Zhangjiakou, Hebei 075000, P.R. China.
FAU - Li, Shuguang
AU  - Li S
AD  - Department of Gastrointestinal Surgical Oncology, The First Affiliated Hospital 
      of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China.
FAU - Yang, Dongdong
AU  - Yang D
AD  - Department of Vascular and Gland Surgery, The First Affiliated Hospital of Hebei 
      North University, Zhangjiakou, Hebei 075000, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20171122
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5774490
OTO - NOTNLM
OT  - colon cancer
OT  - drug resistance
OT  - infliximab
OT  - oxaliplatin
OT  - tumor necrosis factor-alpha
EDAT- 2018/02/13 06:00
MHDA- 2018/02/13 06:01
PMCR- 2017/11/22
CRDT- 2018/02/14 06:00
PHST- 2016/11/16 00:00 [received]
PHST- 2017/09/13 00:00 [accepted]
PHST- 2018/02/14 06:00 [entrez]
PHST- 2018/02/13 06:00 [pubmed]
PHST- 2018/02/13 06:01 [medline]
PHST- 2017/11/22 00:00 [pmc-release]
AID - OL-0-0-7468 [pii]
AID - 10.3892/ol.2017.7468 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Feb;15(2):1517-1522. doi: 10.3892/ol.2017.7468. Epub 2017 Nov 
      22.